1. Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use

   • Sabrina Bagaglio
   • Caterina Uberti-Foppa
   • Giulia Morsica

   Leading Article 12 May 2017 Pages: 1043 - 1055

   

2. Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects

   • Mathurin Flamant
   • Josselin Rigaill
   • Xavier Roblin

   Leading Article 18 May 2017 Pages: 1057 - 1068

   

3. Advanced Analgesic Drug Delivery and Nanobiotechnology

   • Nicoleta Stoicea
   • Juan Fiorda-Diaz
   • Sergio D. Bergese

   Review Article Open access 03 May 2017 Pages: 1069 - 1076

4. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives

   • Matthew S. Farina
   • Kevin T. Lundgren
   • Joaquim Bellmunt

   Review Article 11 May 2017 Pages: 1077 - 1089

   

5. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor

   • Joleen M. Hubbard
   • Axel Grothey

   Review Article 01 June 2017 Pages: 1091 - 1103

6. Ustekinumab: A Review in Moderate to Severe Crohn’s Disease

   • Yvette N. Lamb
   • Sean T. Duggan

   Adis Drug Evaluation 20 May 2017 Pages: 1105 - 1114

   

7. Dupilumab: First Global Approval

   • Matt Shirley

   AdisInsight Report 25 May 2017 Pages: 1115 - 1121

   

8. Valbenazine: First Global Approval

   • Esther S. Kim

   AdisInsight Report 03 June 2017 Pages: 1123 - 1129

   

9. Brigatinib: First Global Approval

   • Anthony Markham

   AdisInsight Report 08 June 2017 Pages: 1131 - 1135

   

10. Comment on: Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors

    • David A. Schoenfeld

    Letter to the Editor 01 June 2017 Pages: 1137 - 1138

11. Authors’ Reply to Schoenfeld: “Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors”

    • Stefan Michiels
    • Everardo D. Saad
    • Marc Buyse

    Letter to the Editor 01 June 2017 Pages: 1139 - 1140

12. Erratum to: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis

    • Bruno Geloneze
    • José Carlos de Lima-Júnior
    • Lício A. Velloso

    Erratum 18 May 2017 Pages: 1141 - 1141